Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Date:8/31/2013

y efficacy outcome was the recurrence of symptomatic VTE, defined as the composite of recurrent symptomatic DVT, non-fatal symptomatic PE and fatal PE in patients during the 12-month study period. The principal safety outcome was clinically relevant bleeding (major or non-major) occurring during or within three days of interrupting or stopping study treatment. Secondary efficacy outcomes included the composite clinical outcome of symptomatic recurrent DVT, non-fatal symptomatic recurrent PE and all-cause mortality.1

The study is named after the famous Japanese artist and painter Katsushika Hokusai.

About Venous Thromboembolism

VTE is an umbrella term for two conditions, DVT and PE. DVT is a blood clot found anywhere in the deep veins of the legs, while PE occurs when part of a clot detaches and lodges in the pulmonary arteries, causing a potentially fatal condition.2

VTE is a major cause of morbidity and mortality worldwide with an annual incidence of approximately one per 1,000 in developed countries, including an estimated 430,000 PE events, 680,000 DVT events and 540,000 deaths each year in the EU.3,4 In the U.S., it is currently estimated that more than 950,000 VTE events and approximately 300,000 VTE related deaths occur each year.5,6 Thirty percent of people with VTE die within one month of diagnosis and about 20% of those with PE experience sudden death.7

About Edoxaban

Edoxaban is an investigational, oral, once-daily anticoagulant that specifically and reversibly inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting.8 The global edoxaban clinical trial program includes two phase 3 clinical studies, Hokusai-VTE and ENGAGE AF-TIMI 48 (Effective aNticoaGulation with Factor XA Next GEneration in Atrial Fibrillation), which are evaluating edoxaban, administered once-daily, for treatment and prevention of re
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
2. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
6. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
7. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
10. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
11. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... keynote address last month that industry is compelled to ... to gain the efficiencies—and develop the transformational innovations -- ... Barsoum,s comments were preceded by Doug Kohrs , ... OMTEC moderator, who stressed that industry must add "episode ...
(Date:7/30/2015)... FAIRFIELD, N.J. , July 30, 2015 /PRNewswire/ ... Ferrer, completed the second Phase III clinical study ... development for impetigo.  Medimetriks owns the exclusive U.S. ... The global trial, conducted at 44 centers with ... and pediatric patients aged 2 months and older ...
(Date:7/30/2015)... Calif. , July 30, 2015   ... to eliminate all preventable hospitalization, recently received confirmation ... its Remote Patient Intelligence (RPI) solution meets the ... FDA intends to exercise "Enforcement Discretion." ... not subject to further FDA regulatory requirements at ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
(Date:7/30/2015)... ... ... Dale Sky Jones, Executive Chancellor of Oaksterdam University , the first ... held at the Caribe Royal All Suites Hotel and Convention Center in Orlando, Florida, ... largest medical cannabis expo in the country and this year’s expo will be the ...
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent ... Fine, an app invention that can help people during emergencies. , "The worldwide ... CEO and Creative Director of World Patent Marketing. "Currently, there are about 97,000 ...
(Date:7/30/2015)... ... July 30, 2015 , ... The connection between a healthy head of hair and a feeling ... a full head of hair can have a devastating impact on the daily life of ... the work place, the consequences of hair loss are not to be taken lightly. , ...
(Date:7/30/2015)... MD (PRWEB) , ... July 30, 2015 , ... ... serving the Mid-Atlantic region, is the recipient of three awards in the Service ... for communications programs created for Choptank Transport, KRM Development Corporation and University of ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... care throughout Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that ... new Palliative Care Administrator. Dr. Demoratz is a strong proponent of early access ...
Breaking Medicine News(10 mins):Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3
... banking initiative by Sir Richard Branson has received a mixed ... the doctors and scientific community,// others opined that it may ... human blood extracted from placenta and umbilical cord is called ... delivered or after the newborn baby is separated from the ...
... people are jetting off for a week of sun, snow, and ... consider the dangers of skin// cancer? ,It is one ... 69,000 new cases reported every year. The incidences of the most ... 20 years. ,Now an online survey aims to ...
... helped obese children to maintain their weight. This game also helped ... cardiac problems and// diabetes. ,In West Virginia, a preliminary ... of 7-12 for a period of six months. Children chosen for ... Dance Revolution’ at home for 30 minutes a day for five ...
... of a number of patients suffering from many forms ... form of treatment for several debilitating diseases. ... the donor attack tissues of the recipient. It is ... related or unrelated donors and may represent a cause ...
... that keeps nerve fibers flexible and a gene is responsible ... to a study//. , A University of Utah ... nematode worms, their nerve cells literally broke. ,The ... 5 (SCA5), a disease previously tied to a human version ...
... experienced jet lag will understand the importance of a ... rhythms// from the natural cycle of light and dark ... photoreceptors that relay signals to the suprachiasmatic nucleus (SCN) ... in peripheral tissues ensure that each clock follows the ...
Cached Medicine News:Health News:The Psychology of Skin Cancer 2Health News:Gene Behind Lincoln’s Diseas 2Health News:Gene Behind Lincoln’s Diseas 3Health News:Researchers Investigate Gene Linked With Circadian Liver Clock 2Health News:Researchers Investigate Gene Linked With Circadian Liver Clock 3
Minimal M9CA Broth...
An agent used for making solid microbiological media....
... of miniTHERM incubators is available, ensuring the ... for their specific requirements. miniTHERM incubators have ... and extremely space saving. Their size corresponds ... is possible to stack up to three ...
In microbiological laboratories and for in vitro fertilization, as well as in cancer research or tissue engineering, the Heraeus CO2 incubator BBD 6220 provides the best contamination protection and ...
Medicine Products: